Drug-Eluting Stents Market By Product Type (Permanent-Polymer Drug-Eluting Stents, Bioabsorbable-Polymer Drug-Eluting Stents, Polymer-Free Drug-Eluting Stents, Bioresorbable Drug-Eluting Scaffolds); By Drug Type (Everolimus-Eluting Stents, Zotarolimus-Eluting Stents, Sirolimus-Eluting Stents, Ridaforolimus-Eluting Stents, Other Drug-Eluting Stents); By Application (Stable Coronary Artery Disease, ST-Elevation Myocardial Infarction, Non-ST-Elevation Myocardial Infarction, Unstable Angina, Complex Coronary Lesions, In-Stent Restenosis); By End User (Hospitals and Cardiac Centers, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Drug-Eluting Stents Market: Procedure Access and Complex Coronary Disease Matter More Than Headline Prevalence

The Global Drug-Eluting Stents Market was valued at USD 4.25 billion in 2025 and is projected to reach USD 6.69 billion by 2032, expanding at a CAGR of 6.7% during 2026–2032, according to Strategic Market Research.

 

Drug-eluting stents (DES) are permanent or bioresorbable vascular scaffolds coated with a polymer that gradually releases therapeutic drugs. Their primary mechanism of action is anti-proliferative and anti-inflammatory, helping suppress excessive smooth muscle cell growth after stent placement. This controlled drug release promotes arterial healing while maintaining vessel patency. As a result, DES significantly reduce the risk of in-stent restenosis, or re-narrowing of the treated artery.

 

Coronary DES Is a Device-Led Intervention, Not a Standalone Drug Treatment

A coronary DES is implanted through a catheter during percutaneous coronary intervention. The scaffold provides mechanical support, while its coating releases drugs such as everolimus, zotarolimus, sirolimus or ridaforolimus to suppress excessive smooth-muscle-cell growth.

The U.S. Food and Drug Administration regulates coronary DES as Class III implanted devices and drug-device combination products. The commercial demand unit is one stent implanted rather than one diagnosed patient, prescription or procedure. A PCI may use no stent, one stent or several stents, particularly in long, bifurcated or multivessel disease.

Hospitals and cardiac centers accounted for 72.0% of market revenue in 2025, equivalent to USD 3.060 billion. Their position reflects the concentration of emergency myocardial infarction treatment, complex PCI, surgical backup and high-risk patient management within full-service cardiovascular facilities. This segment is projected to reach USD 4.616 billion by 2032, although its share is expected to decrease to 69.0% as it grows at a CAGR of 6.0%.

Dedicated cardiac catheterization laboratories represented 23.0% of the market and USD 0.978 billion in 2025. They are expected to be the fastest-growing end-user category, expanding at a CAGR of 8.6% to reach USD 1.739 billion and a 26.0% share by 2032. New catheterization laboratories, greater procedure throughput, wider intravascular imaging use and more complex coronary interventions are moving a larger share of DES purchasing toward specialized facilities.

Ambulatory surgical centers accounted for 5.0% of the market and USD 0.213 billion in 2025. The segment is forecast to reach USD 0.335 billion by 2032 at a CAGR of 6.7%, while retaining its 5.0% share. Growth remains selective because coronary intervention requires strict patient selection, emergency-transfer protocols, advanced imaging and specialized cardiovascular support.

DES remains part of a wider care pathway. Patients generally continue antiplatelet and secondary-prevention medication after implantation, while cardiac rehabilitation may follow myocardial infarction or PCI. These services complement stenting but do not represent DES utilization.

 

Acute Coronary Events Sustain a Large Urgent-Procedure Base

Acute myocardial infarction remains one of the strongest sources of urgent PCI demand. Approximately 805,000 heart attacks occur annually in the United States, including about 605,000 first events and 200,000 recurrent events. Emergency treatment of STEMI and selected NSTEMI patients creates a continuing procedure base that is less dependent on elective scheduling.

ST-elevation myocardial infarction accounted for 18.0% of the DES market and USD 0.765 billion in 2025. The segment is projected to reach USD 1.204 billion by 2032 at a CAGR of 6.7%, retaining its 18.0% share. Emergency primary PCI networks and continued implantation during culprit-vessel intervention support a stable demand base.

Non-ST-elevation myocardial infarction represented 15.0% of the market and USD 0.638 billion in 2025. It is expected to reach USD 1.070 billion and a 16.0% share by 2032, expanding at a CAGR of 7.7%. Growth is supported by wider early invasive management and increasing angiography and PCI rates among higher-risk NSTEMI patients.

Unstable angina accounted for 10.0% of the market and USD 0.425 billion in 2025. Revenue is forecast to reach USD 0.602 billion by 2032, while its share declines to 9.0% at a CAGR of 5.1%. Improved cardiac biomarker sensitivity and changing acute coronary syndrome classification are shifting some patients into NSTEMI and other diagnostic categories.

Stable coronary artery disease remained the largest application, representing 34.0% of the market and USD 1.445 billion in 2025. Planned PCI continues to account for substantial DES implantation, but the segment is projected to grow at a below-market CAGR of 5.3%, reaching USD 2.074 billion and a 31.0% share by 2032. Greater physiological lesion assessment and continued medical management for selected stable patients will restrain faster expansion.

Coronary disease also remains a major mortality burden. Coronary heart disease caused 349,470 U.S. deaths in 2023, while myocardial infarction accounted for 93,345 deaths within that wider total. Globally, ischemic heart disease caused an estimated 8.99 million deaths in 2021, while WHO reported approximately 9.1 million.

The American Heart Association reported 435,895 U.S. PCI procedures in 2022, while SCAI has separately stated that almost one million PCIs are performed annually in the United States and more than two million globally. The difference reflects varying data coverage, but both sources confirm that procedure capacity remains a central commercial driver.

 

Complex Lesions Are Shifting Value Toward Broader Portfolios

Complex coronary lesions accounted for 16.0% of the market and USD 0.680 billion in 2025. The segment is projected to become the fastest-growing application, reaching USD 1.338 billion and a 20.0% share by 2032 at a CAGR of 10.2%.

Long lesions, bifurcations, calcified vessels, chronic total occlusions, left-main disease and multivessel interventions may require multiple implants, longer stents, intravascular imaging or specialized lesion-preparation equipment. These cases can increase revenue per procedure and reward suppliers with broad size matrices, strong deliverability and approved complex-lesion indications.

Medtronic’s Onyx Frontier is indicated for de novo chronic total occlusions and specified non-left-main bifurcation lesions treated with a provisional technique. Its portfolio also supports one-month dual-antiplatelet therapy for selected high-bleeding-risk patients.

Boston Scientific’s SYNERGY XD covers stable angina, unstable angina, STEMI, NSTEMI, silent ischemia, diabetes and defined high-bleeding-risk populations. Its 48 mm option addresses selected long lesions and may reduce the need to overlap multiple stents, supporting shorter procedures and simpler inventory management.

Abbott expanded its XIENCE Skypoint offering in India in March 2026 with sizes intended for long lesions, large vessels and selected left-main procedures. Such launches show that established suppliers are competing through indication breadth, difficult-anatomy access and complete product ranges rather than basic drug-elution capability alone.

 

Shorter Antiplatelet Strategies Are Becoming a Procurement Advantage

Bleeding risk is becoming a more important source of differentiation. Prolonged dual-antiplatelet therapy can be difficult for older patients, people taking anticoagulants and those with prior bleeding, stroke, renal impairment or planned surgery.

Medtronic’s Onyx platform supports one-month DAPT for selected high-bleeding-risk patients in the United States. Boston Scientific’s SYNERGY portfolio supports a shortened three-month strategy for specified U.S. patients. Terumo received an expanded European MDR indication in 2025 for Ultimaster Nagomi and Ultimaster Tansei, covering eligible high-bleeding-risk patients with DAPT as short as one month.

These indications affect hospital purchasing as well as clinical positioning. A platform that can serve routine, acute and high-bleeding-risk patients may simplify procurement and improve physician confidence. Shortened DAPT evidence can also widen DES use among patients previously considered difficult candidates.

 

Mature Drug Classes Increase Pressure on Scaffold and Delivery Design

Everolimus-eluting stents held the largest drug-type share at 48.0% in 2025, generating USD 2.040 billion. Their leadership reflects extensive clinical use, broad regulatory availability and incorporation into major permanent- and bioabsorbable-polymer platforms. The segment is forecast to reach USD 3.011 billion by 2032 at a CAGR of 5.7%, although its share is expected to decrease to 45.0%.

Zotarolimus-eluting stents accounted for 18.0% of the market and USD 0.765 billion in 2025. The segment is projected to reach USD 1.137 billion by 2032 at a CAGR of 5.8%, with its share moderating to 17.0%. Established use within multinational coronary portfolios will maintain its importance across mature PCI systems.

Sirolimus-eluting stents represented 25.0% of the market and USD 1.063 billion in 2025. The segment is expected to be the fastest-growing major drug category, expanding at a CAGR of 9.0% to reach USD 1.940 billion and a 29.0% share by 2032. Growth is supported by thin-strut systems, biodegradable-polymer and polymer-free designs, regional manufacturing and competitively priced European and Asia-Pacific platforms.

Ridaforolimus-eluting stents accounted for a 4.0% share and USD 0.170 billion in 2025. The segment is projected to reach USD 0.268 billion by 2032 while retaining a 4.0% share and growing at 6.7%. Other drug-eluting stents, including paclitaxel-, biolimus- and novolimus-based systems, represented 5.0% of the market and USD 0.213 billion in 2025. This category is forecast to reach USD 0.335 billion by 2032 while maintaining its 5.0% share.

Because the leading drugs address the same broad restenosis pathway, purchasing decisions increasingly depend on deliverability, strut thickness, visibility, radial strength, vessel-size coverage, available lengths, over-expansion capability, polymer characteristics, clinical evidence and supply continuity.

Medinol received FDA approval for EluNIR-PERL in October 2023. The system added radiopaque markers and delivery changes intended to improve placement visibility, showing that newer entrants can compete through procedural improvements without introducing an entirely new drug.

Teleflex strengthened its interventional portfolio by completing the €760 million acquisition of substantially all of BIOTRONIK’s vascular-intervention business in July 2025. The transaction brought Orsiro Mission into a wider catheterization-laboratory portfolio and created opportunities to combine stents with access and specialty-catheter products.

 

Polymer Choice Will Remain One Part of a Wider Value Proposition

Permanent-polymer drug-eluting stents represented 62.0% of the market and USD 2.635 billion in 2025. Their leadership reflects extensive clinical evidence, established approvals, physician familiarity and availability across routine and complex PCI. The segment is projected to reach USD 3.813 billion by 2032, although its share is expected to decline to 57.0% as it grows at a CAGR of 5.4%.

Bioabsorbable-polymer DES accounted for 24.0% of the market and USD 1.020 billion in 2025. Their share is projected to increase to 27.0%, equivalent to USD 1.806 billion, by 2032 at a CAGR of 8.5%. Adoption is being supported by interest in maintaining controlled drug release while reducing long-term polymer exposure after coating degradation.

Polymer-free drug-eluting stents generated USD 0.468 billion and represented 11.0% of the market in 2025. The segment is expected to reach USD 0.803 billion and a 12.0% share by 2032, expanding at a CAGR of 8.0%. These products are gaining strategic relevance where physicians seek to avoid permanent polymer coatings, including selected high-bleeding-risk patients.

Hospitals evaluate polymer choice together with pricing, delivery performance, indication breadth, clinical evidence, available dimensions, contractual relationships and supply reliability. No single polymer approach has displaced the others across all lesions and patient groups.

 

Bioresorbable Scaffolds Are Returning Under Stricter Evidence Standards

Bioresorbable drug-eluting scaffolds accounted for 3.0% of the market and USD 0.128 billion in 2025. Although still a small category, the segment is projected to record the fastest product-level CAGR of 11.2%, reaching USD 0.268 billion and a 4.0% share by 2032.

These scaffolds aim to provide temporary vessel support before gradually disappearing. The concept remains commercially attractive because it could remove the permanent metallic cage after healing. However, Abbott’s Absorb BVS was withdrawn after studies found higher myocardial infarction and scaffold-thrombosis rates than the XIENCE metallic DES comparator.

Later platforms must demonstrate predictable implantation, sufficient early radial strength, controlled resorption, thinner scaffold profiles and long-term safety in realistic lesion populations.

Teleflex initiated enrolment in the global BIOMAG-III pivotal trial for its Freesolve resorbable magnesium scaffold in June 2026. The randomized study plans to enrol 1,859 patients at up to 120 sites, including as many as 60 U.S. sites, and will compare Freesolve with Abbott’s XIENCE DES. Freesolve received a CE mark in 2024 and represents one of the more advanced attempts to re-enter the resorbable scaffold category.

Bioadaptor systems are following a related path. Elixir Medical’s DynamX initially supports the artery and later allows greater vessel movement after parts of the implant mechanically separate. These systems could compete with permanent DES if long-term studies demonstrate fewer adverse events or repeat interventions. Gene-eluting and coordinated multi-drug stents remain early-stage concepts and are unlikely to contribute materially to near-term revenue.

 

Drug-Coated Balloons Are Creating a Targeted Substitute in Restenosis

In-stent restenosis accounted for 7.0% of the DES market and USD 0.298 billion in 2025. The segment is projected to grow at a slower CAGR of 4.4%, reaching USD 0.401 billion and a 6.0% share by 2032.

Growth is being moderated by drug-coated balloons, lesion-modification technologies and individualized treatment based on the cause of restenosis. In February 2024, FDA approved Boston Scientific’s AGENT paclitaxel-coated balloon for coronary ISR, making it the first U.S.-approved coronary DCB. It delivers an antiproliferative drug without placing another permanent metal layer inside the existing stent.

The substitution remains targeted. De novo obstructive lesions, vessel recoil, dissections and many complex anatomies still require mechanical scaffolding. Suppliers with DES, DCB, imaging and lesion-preparation portfolios may be better positioned as treatment moves toward lesion-specific device selection.

 

Regional Performance Reflects Procedure Capacity and Procurement Structure

North America held the largest regional share at 38.0% in 2025, representing USD 1.615 billion. High PCI expenditure, established reimbursement, advanced DES access and substantial intravascular imaging use support its leadership. The region is projected to reach USD 2.342 billion by 2032 at a CAGR of 5.4%, while its share declines to 35.0%.

Europe accounted for 29.0% of the market and USD 1.233 billion in 2025. Revenue is forecast to reach USD 1.806 billion by 2032 at a CAGR of 5.6%, with its share moderating to 27.0%. Established interventional infrastructure, broad biodegradable-polymer and polymer-free stent use, and access to regional and multinational manufacturers sustain demand.

Asia-Pacific represented 25.0% of the market and USD 1.063 billion in 2025. It is projected to be the fastest-growing region, expanding at a CAGR of 9.5% to reach USD 2.007 billion and a 30.0% share by 2032. Rising coronary disease diagnosis, higher PCI volumes, new catheterization laboratories, expanding insurance coverage and competitively priced domestic DES products are narrowing the gap with North America and Europe.

Abbott’s XIENCE Skypoint launch in India and MicroPort’s presence in more than 4,000 Chinese hospitals and over 3,000 hospitals outside China show how multinational and regional suppliers are expanding simultaneously. Japan, South Korea and Australia have mature interventional systems, while access in parts of South and Southeast Asia remains concentrated in major urban hospitals.

Latin America accounted for 4.5% of the market and USD 0.191 billion in 2025. It is forecast to reach USD 0.301 billion by 2032 at a CAGR of 6.7%, retaining its 4.5% share. The Middle East and Africa represented 3.5% and USD 0.149 billion in 2025 and are expected to reach USD 0.234 billion by 2032 at the same CAGR. Growth in both regions will depend on PCI-capable hospital investment, specialist availability, reimbursement expansion and reliable distribution.

 

Competitive Pressure Is Moving Beyond Individual Stent Design

The directly verifiable competitive group includes Abbott, Boston Scientific, Medtronic, Teleflex, Medinol, Terumo and MicroPort. Competition extends across product breadth, approved indications, difficult-lesion performance, long-term evidence, hospital tender pricing, physician support, local manufacturing and regulatory timing.

Teleflex’s BIOTRONIK vascular-intervention acquisition demonstrates the value of combining coronary implants with a wider catheterization-laboratory portfolio. MicroPort’s international expansion shows that Chinese suppliers are moving beyond domestic procurement into European, Asian and Latin American markets.

 

Market Constraint: Clinical Selection Limits Addressable Demand

Guidelines continue to favor CABG for several high-complexity multivessel and left-main scenarios. In FAME 3, FFR-guided PCI with current-generation DES did not meet its original non-inferiority objective against CABG in three-vessel disease, and later follow-up showed more myocardial infarction and repeat revascularization in the PCI group.

Wider use of FFR, iFR and angiography-derived flow measurement may restrain low-value implantation while improving case selection. This will shift commercial value toward patients with clearer clinical benefit and more complex treatment requirements.

 

Analyst Perspective: Revenue Growth Will Come From Complexity, Access and Portfolio Breadth

Coronary DES are permanent implants and do not create a scheduled replacement cycle. Repeat demand arises from new lesions, staged multivessel PCI and reintervention. Market growth will therefore depend on procedure flow, lesion complexity and revenue per case rather than installed-base replacement.

The strongest opportunities will come from expanding PCI capacity, treatment of complex lesions, shorter DAPT indications, broader size matrices, combined DES and DCB portfolios, and regulatory progress for resorbable magnesium scaffolds and bioadaptors.

 

Drug-Eluting Stents Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.25 Billion
Revenue Forecast in 2032	USD 6.69 Billion
Overall Growth Rate	CAGR of 6.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Drug Type, By Application, By End User, By Geography
By Product Type	Permanent-Polymer Drug-Eluting Stents, Bioabsorbable-Polymer Drug-Eluting Stents, Polymer-Free Drug-Eluting Stents, Bioresorbable Drug-Eluting Scaffolds
By Drug Type	Everolimus-Eluting Stents, Zotarolimus-Eluting Stents, Sirolimus-Eluting Stents, Ridaforolimus-Eluting Stents, Other Drug-Eluting Stents
By Application	Stable Coronary Artery Disease, ST-Elevation Myocardial Infarction, Non-ST-Elevation Myocardial Infarction, Unstable Angina, Complex Coronary Lesions, In-Stent Restenosis
By End User	Hospitals and Cardiac Centers, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of coronary artery diseases, increasing adoption of minimally invasive cardiac interventions, growing demand for advanced stent technologies, and expansion of cardiovascular care infrastructure
Customization Option	Available upon request